• 한국임상수의학회:학술대회논문집
• /
• 한국임상수의학회 2009년도 춘계학술대회
• /
• pp.282-282
• /
• 2009

• 대한영상의학회지
• /
• 제84권6호
• /
• pp.1198-1210
• /
• 2023

최근에 우연히 발견되는 신장 종괴의 증가와 국소 치료, 표적 치료와 같은 신장암 치료 선택지의 다양화, 그리고 신장 이식의 보편화에 따라서 신장의 조직 검사가 증가하고 있는 추세이다. 그러나 신장은 피부부터 장기까지의 거리가 멀어 조직 검사의 난이도가 높은 편으로 특히 초심자들은 신장의 조직 검사를 부담스럽게 여길 수 있다. 이 종설에서 우리는 신장 조직 검사의 적응증과 기술적인 고려 사항들, 진단 정확도, 그리고 합병증에 대해서 알아보겠다. 특히 실전적인 팁들을 다양한 증례들과 함께 알아보며 다양한 상황에서도 안전하고 효과적으로 조직 검사를 시행할 수 있게 도움이 되고자 한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권3호
• /
• pp.2101-2105
• /
• 2013

Background: Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as a second line treatment in metastatic renal cell carcinoma (mRCC) are limited. Prognostic and predictive value of peripheral blood markers has been shown for many cancers. Materials and Methods: Efficacy and safety profiles of sunitinib after interferon alpha (IFN-${\alpha}$) were evaluated based on retrospective data for 23 patients with mRCC. Hematological parameters (neutrophils, lymphocytes, platelets, mean platelet volume, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio) were recorded at the time of metastasis. It was evaluated whether hematological parameters were prognostic and predictive factors. Results: Median progression-free survival (PFS) time was 16.5 months (95%CI: 0-34.5). Median overall survival (OS) time was 25.7 months (95%CI: 10.8-40.0). Most common side effects were neutropenia (52.2%), stomatitis (26.1%) and hand-food syndrome (26.1%). PFS was found 3.13 vs 17.1 months in patients with neutrophil / lymphocyte ratio (NLR)>3 vs $NLR{\leq}3$ (p:0.012). Median OS was 6.96 vs 27.1 months in patients with NLR>3 vs $NLR{\leq}3$ (p:0.001).While 75% of patients who responded to sunitinib had $NLR{\leq}3$, in 72% of patients with no response to sunitinib NLR>3 was detected (p:0.036). The association between the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria and NLR was statistically significant (p:0.022). Conclusions: Data on second line sunitinib treatment following cytokine in mRCC are limited. In our study, we observed second line sunitinib treatment following IFN-${\alpha}$ to be effective and tolerable. NLRappeared to have prognostic and predictive value.

• Journal of Chest Surgery
• /
• 제3권2호
• /
• pp.143-148
• /
• 1970

Bleomycin is known as a antibiotic agent for malignant tumors especially sguamous cell carcinoma. We have treated 2 cases of malignant tumors, each one esophageal and lung carcinoma with bleomycin, 630 mg and 510 mg respectively. In case of esophageal carcinoma. the subjective symptoms such as dysphagea and swallowing disturbance are temporally relieved, but the irregular filling defect is not significantly changed in esophagogram. In case of lung carcinoma, the atelectasis of right upper lobe on chest X-ray was slightly regressed in its size without effective improvement of subjective symptoms. However, following additional radioactive $^60{Co}$ irradiation therapy (5200r), marked regression of tumor density and aeration of right upper lobe was observed. But 2 weeks later of ceasatioil of irradiatio:J, atelectasis of right upper lobe was again developed. Fever, anorexia, headache and eruption were developed during the treatmeat with bleomycin in both cases but the sign or symptoms of hone marrow depression, renal or liver damage were not noted.

• IMMUNE NETWORK
• /
• 제3권2호
• /
• pp.96-102
• /
• 2003

Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced tumor cell vaccines induce very potent systemic anti-tumor immunity in preclinical and clinical models. Our previous phase I clinical trial in patients with metastatic renal cell carcinoma (RCC) has demonstrated both immune cell infiltration at vaccine sites and T cell-mediated delayed-type hypersensitivity (DTH) response to whole tumor cell vaccines. Methods: To investigate the immune responses to autologous genetically- modified tumor cell vaccines, tumor-specific $CD8^+$ T cell lines were generated from peripheral blood lymphocytes (PBL) of a RCC patient 1.24 by repeated in vitro stimulation with either B7.1-transduced autologous RCC tumor cells or B7.1-transduced autologous tumor cells treated with interferon gamma ($IFN{\gamma}$), and cloned by limiting dilution. Results: Among several RCC-specific cytotoxic T lymphocytes (CTLs), a $CD4^+/CD8^+$ double positive T cell clone (17/A2) appeared to recognize $IFN{\gamma}$-treated autologous RCC restricted by HLA-B39. The 17/A2 also recognized other HLA-B39 positive RCC tumor cells after $IFN{\gamma}$ treatment. Conclusion: These results demonstrate that autologous RCC vaccination successfully generates the tumor-specific CTL 17/A2, and suggest that the presentation and recognition of the tumor antigen by the 17/A2 might be upregulated by $IFN{\gamma}$.

• 대한세포병리학회:학술대회논문집
• /
• 대한세포병리학회 1991년도 제5차 춘계학술대회 초록집
• /
• pp.17.1-17.1
• /
• 1991

• Journal of Korean Neurosurgical Society
• /
• 제30권8호
• /
• pp.1023-1027
• /
• 2001

Hemangioblastomas are rare benign tumor of the central nervous system that commonly occur in the posterior fossa around the 4th ventricle. In case of von Hippel-Lindau disease, hemangioblastomas involve multiple regions such as cerebellum, spinal cord and brainstem but, rarely show simultaneous involvement of cerebellum and spinal cord. We have experienced a case of multiple hemangioblastomas that were located at the cerebellum, cervical cord and conus medullaris and also had multiple lesions that a part of von Hippel-Lindau disease ; retinal angioma, syringomyelia, multiple cyst on kidney and pancreas, renal cell carcinoma on left kidney. Hemangioblastomas on cerebellum and spinal cord were removed totally, retinal angioma was treated with laser photocoagulation and renal cell carcinoma was also totally excised. The authors report a case of von Hippel-Lindau disease had multiple located hemangioblastomas on cerebellum, cervical cord and conus medullaris with review of literature.

• 대한골관절종양학회지
• /
• 제13권2호
• /
• pp.113-118
• /
• 2007

골반 골에 생기는 종양은 복잡한 해부학적 구조와 체부 깊숙이 위치하는 특성으로 인하여, 상당히 커진 후에야 발견되는 경우가 많아서 진단이 늦어지고, 수술이 어려워지는 경우가 많이 있다. 특히 비구 주위에 발생한 종양은 종양의 제거 후에 고관절의 기능을 유지 할 수 있는 재건술의 방법이 극히 제한되어 있고, 수술도 어려우며, 재건술의 예후 또한 예측하기 어렵다. 저자는 신장암이 골반 골 비구 주위로 단독 전이 된 환자의 광범위 종양절제 후 저온 가열 처리한 자가골 과 인공고관절로 재건 한 증례를 보고한다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제4권2호
• /
• pp.159-167
• /
• 2000

We have synthesized a novel platinum(II) coordination complex containing cis-1,2-diaminocyclohexane (DACH) as a carrier ligand and 1,2-dichloroethane (DCE) as a leaving group. In addition, nitrate was added to improve the water-solubility. A new series of [Pt(cis-DACH)(DCE)] $2NO_3(PC)$ was evaluated for its cytotoxic activity on T-24 and J-82 human bladder carcinoma cells and normal primary cultured kidney cells. PC has demonstrated high levels of cytotoxicity against T-24 and J-82 cells. The cytotoxicity of PC against rabbit proximal renal tubular cells, human renal cortical cells and human renal cortical tissues, determined using the MTT assaying technique, the $[^3H]-thymidine$ uptake and glucose consumption tests, was found to be quite less than those of cisplatin. Based on these results, this novel platinum(II) coordination complex appears to be better for improving antitumor activities with low nephrotoxicity and is a valuable lead in the development of new clinically available anticancer chemotherapeutic agents.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권23호
• /
• pp.10217-10223
• /
• 2015

Hyperactivated ${\alpha}2$-6-sialylation on N-glycans due to overexpression of the Golgi enzyme ${\beta}$-galactoside: ${\alpha}2$-6-sialyltransferase (ST6Gal-I) often correlates with cancer progression, metastasis, and poor prognosis. This study was aimed to determine the association between ST6Gal-I expression and the risk of recurrence and survival of patients with localized clear-cell renal cell carcinoma (ccRCC) following surgery. We retrospectively enrolled 391 patients (265 in training cohort and 126 in validation cohort) with localized ccRCC underwent nephrectomy at a single center. Tissue microarrays were constructed for immunostaining of ST6Gal-I. Prognostic value and clinical outcomes were evaluated. High ST6Gal-I expression was associated with Fuhrman grade (p<0.001 and p=0.016, respectively) and the University of California Los-Angeles Integrated Staging System (UISS) score (p=0.004 and p=0.017, respectively) in both cohorts. Patients with high ST6Gal-I expression had significantly worse overall survival (OS) (p<0.001 and p<0.001, respectively) and recurrence free survival (RFS) (p<0.001 and p=0.002, respectively) than those with low expression in both cohorts. On multivariate analysis, ST6Gal-I expression remained associated with OS and RFS even after adjusting for the UISS score. Stratified analysis suggested that the association is more pronounced among patients with low and intermediate-risk disease defined by the UISS score. High ST6Gal-I expression is a potential independent adverse predictor of survival and recurrence in ccRCC patients, and the prognostic value is most prominent in those with low and intermediate-risk disease defined by the UISS score.